Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 15/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161222 | 0.89 | MEN1 (0.35) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10160980 | 0.89 | MEN1 (0.39) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10160888 | 0.88 | MAPT (0.34) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10160934 | 0.85 | SOS1 (0.33) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10161197 | 0.85 | MAPT (0.41) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10160928 | 0.84 | MMP13 (0.33) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10161069 | 0.83 | ALDH1A1 (0.32) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10160466 | 0.82 | MAPT (0.36) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10160922 | 0.81 | ALOX5 (0.31) | MAPTSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL10160927 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| US-20120115819-A1 | Pentacycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-05-10 | — | — | US | disclosed |
| WO-2010132670-A2 | PENTACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115819-A1 | Pentacycline Compounds | TSLP, IL5, IL17A | MAPT 734/4885SMN1; SMN2 3883/4885MEN1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.